A Multicentric, Prospective, Randomized Study Evaluating the Improvement of Renal Function Outcomes With Dorzagliatin in Patients With Type 2 Diabetes Mellitus With Early Kidney Injury.

The main purpose of this study is to explore the improvement of renal function before and after the intervention of dorzagliatin in patients with type 2 diabetes.

Start Date20 Feb 2024

Sponsor / Collaborator-

ChiCTR2400079946 / SuspendedPhase 4IIT

Predictive model of achieving glycemic target with Glucokinase agonist Dorzagliatin for type 2 diabetes:based on a real world study from China

Start Date31 Jan 2024

Sponsor / Collaborator-

CTR20233169 / RecruitingPhase 4

一项多中心上市后观察性研究，评价多格列艾汀在2型糖尿病患者中的长期用药安全性

[Translation] A multicenter post-marketing observational study to evaluate the long-term safety of dopagliflozin in patients with type 2 diabetes

本研究的主要目的是通过收集多格列艾汀上市后临床用药安全性数据，评价本品在更大样本2型糖尿病人群中的长期用药安全性。

[Translation]

The main purpose of this study is to collect post-marketing clinical safety data of dogliflozin and to evaluate the long-term safety of this product in a larger sample of type 2 diabetes population.

Start Date20 Dec 2023

Sponsor / Collaborator

Shanghai Desano Pharmaceuticals Co. Ltd.

[+1]

100 Clinical Results associated with Dorzagliatin

100 Translational Medicine associated with Dorzagliatin

100 Patents (Medical) associated with Dorzagliatin

Literatures (Medical) associated with Dorzagliatin

01 Feb 2024·Diabetes, obesity & metabolism

Improvement of early‐phase insulin secretion is an independent factor for achieving glycaemic control: A pooled analysis of SEED and DAWN study

Article

Author: Guo, Quanle ; Yang, Wenying ; Feng, Lingge ; Chen, Chunxiang ; Chen, Li

Abstract:

Aim:

To investigate the effect of improving early phase insulin secretion function for glycaemic control in patients with type 2 diabetes mellitus treated with a new class of antidiabetic drug dorzagliatin.

Materials and Methods:

Early insulin secretion function was studied in 726 participants of which 414 were treated with dorzagliatin in the SEED and DAWN study. The early insulinogenic index (IGI30min) and disposition index (DI) were used to assess early‐phase insulin secretion function in this study. Logistic regression analysis was performed to verify the importance of IGI30min and DI indices for achieving effective glycaemic control.

Results:

The reduction in HbA1c has a significant correlation with the improvement of IGI30min for patients that received 24 weeks of dorzagliatin treatment (p < .001), and this correlation was not observed in the placebo group (p = .364). In the dorzagliatin treatment group, the responders showed significant improvements in homeostasis model assessment 2‐β, IGI30min and DI compared with the non‐responders. Logistic regression analysis revealed that the odds ratio (OR) for achieving glycaemic control was 1.28 (95% CI 1.14‐1.43) for baseline IGI30min, and 1.24 (95% CI 1.14‐1.35) for the 24‐week incremental IGI30min from baseline. The OR for baseline DI and 24‐week changes in DI from baseline were 1.39 (95% CI 1.2‐1.6) and 1.30 (95% CI 1.19‐1.43) respectively. The timing of insulin secretion analysis showed the significant contribution of early‐phase insulin secretion, rather than late‐phase insulin secretion, to postprandial glucose control with the OR for the incremental IGI30min and IGI2h to postprandial glucose control were 1.3 (95% CI 1.19‐1.42) and 1 (95% CI 1‐1.01) respectively.

Conclusions:

Restoring the impaired early‐phase insulin secretion function in patients with type 2 diabetes mellitus is a critical factor for improving the glycaemic control by dorzagliatin treatment.

27 Dec 2023·International journal of endocrinology

Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus

Article

Author: Zhou, Yunting ; Ma, Jianhua ; Zhou, Xiao ; Zhang, Wenli ; Wang, Yuming ; Yang, Wei ; Li, Huiqin ; Su, Xiaofei

Aim. The prevalence rate of type 2 diabetes mellitus (T2DM) has been increasing and a large proportion of patients still do not achieve adequate or sustainable glycemic control on the basis of previous hypoglycemic treatment. In this present study, we explored whether dorzagliatin, a novel glucokinase activator (GKA), could improve glycemic control and lessen glucose fluctuation in drug-naïve patients with T2DM. Methods. A self-comparative observational study of 25 drug-naïve patients with T2DM (aged 18–75 years and HbA1c of 7.5%–11.0%) treated with dorzagliatin 75 mg twice daily for 52 weeks. Before and after dorzagliatin intervention, the serum levels of hemoglobin A1c (HbA1c), insulin, and C-peptide were measured repeatedly during fasting and after a mixed meal. The continuous glucose monitoring (CGM) device was also used to obtain 24-hour glucose profiles and assess the changes in glycemic variability parameters. Results. After 52 weeks of treatment with dorzagliatin, a numerally greater reduction in HbA1c of 1.03% from the baseline was observed in patients with T2DM, accompanied by significant improvement in insulin resistance and insulin secretion. Moreover, the standard deviation of blood glucose (SDBG) and the mean amplitude of glycemic excursion (MAGE) derived from CGM data were significantly decreased after dorzagliatin therapy. The 24-h glucose variation profile showed that study patients had obviously lower mean glucose levels during the postprandial period from the baseline to week 52, an effect also demonstrated by the significant decrease in the incremental area under glucose concentration versus time curve for 2 h (iAUC0–2 h) after meals. Conclusions. This study suggests that dorzagliatin therapy could effectively improve glycemic control and glucose fluctuation in drug-naïve patients with T2DM.

01 Dec 2023·Clinical therapeutics

Dorzagliatin for Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Phase II/III Trials

Review

Author: He, Rong ; Jiang, Ting ; Yu, Bin ; Wang, Lin ; Ling, Baodong ; Lin, Fei

PURPOSE:

Dorzagliatin is a glucokinase agonist with effects on type 2 diabetes mellitus (T2DM). This study included a meta-analysis on the efficacy and safety of dorzagliatin in the treatment of T2DM.

METHODS:

The Cochrane Central Registry of Controlled Trials, PubMed, and Embase were searched from inception to July 25, 2022. A total of 3 studies including 1333 patients were identified in this meta-analysis.

FINDINGS:

Overall, the meta-analysis showed that dorzagliatin remarkably reduced glycated hemoglobin levels versus placebo by 0.66%. The results of the meta-analysis showed a significant reduction in fasting plasma glucose of 6.77 mg/dL between dorzagliatin and placebo. In addition, dorzagliatin reduced 2-hour postprandial glucose (2h-PPG) by 43.87 mg/dL compared with placebo. Furthermore, the meta-analysis of available data revealed a significant reduction in the Homeostasis Model Assessment of Insulin Resistance of 0.07 between dorzagliatin and placebo. The risk of adverse events was slightly higher with dorzagliatin than with placebo.

IMPLICATIONS:

Dorzagliatin significantly reduced glycated hemoglobin levels, fasting plasma glucose levels, 2h-PPG, and homeostasis model assessment 2 of insulin resistance in patients with T2DM. It was well tolerated and had good liver and kidney safety profiles.

News (Medical) associated with Dorzagliatin

16 Feb 2023

·www.prnewswire.com

111, Inc. Hosts Hua Medicine Launches First Official Flagship Store

SHANGHAI, Feb. 16, 2023 /PRNewswire/ -- On February 15, 2023, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced that during the HuaTangNing® Market Launch for Innovative Commerce Cooperation, Dr. Yu Gang, Co-founder and Executive Chairman of 111, and Dr. Chen Li, Founder and CEO of Hua Medicine (HKEx stock code: 2552.HK), jointly unveiled the plaque of Hua Medicine's first official online flagship store on 111. 111 is committed to digitally connecting patients with medicine and healthcare services, aspiring to build itself into an integrated online and offline healthcare platform. The official flagship store launched by Hua Medicine on 111 will serve as an official window to showcase the outstanding brand image of Hua Medicine and an important platform for Hua Medicine to better serve both patients and doctors. For its part, 111 will further help Hua Medicine expand its commercial layout, broaden its drug supply and distribution channels, and explore innovative and diversified supply service modes. The official flagship store will provide patients with Hua Medicine's innovative treatment concepts, carry out patient education on drug safety and other topics, and release the latest news from Hua Medicine. Dr. Yu Gang, Co-founder and Executive Chairman of 111, said: "Hua Medicine is a leader in innovative drug research and commercialization in China. Over the years, it has devoted itself to the research and development of original drugs. HuaTangNing®, a first-in-class drug of its kind, is from Hua Medicine. The official opening of its flagship store on 111 is a timely and innovative measure taken by a Chinese innovative pharmaceutical company to embrace the Internet. At the same time, it also marks a key milestone for 111 and Hua Medicine in the exploration of online cooperation. 111 will work with Hua Medicine to make cutting-edge innovative drugs more accessible for diabetes patients, empower diabetes treatment as well as patient management, and contribute value to society." Dr. Li Chen, Founder and CEO of Hua Medicine, said: "111 is a benchmark player in China's Internet medicine and healthcare industry, equipped with leading digital technology and smart supply chain. We are very much looking forward to Hua Medicine's cooperation with 111, as we provide innovative solutions of health management and medical services through the online flagship store. In the future, Hua Medicine will continue to explore partnership opportunities with Internet channels to benefit more diabetic patients." About Hua Medicine Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care. As Hua Medicine's cornerstone product (dorzagliatin tablets), targeting the glucose sensor, glucokinase, restores glucose sensitivity in T2D patients and stabilizes the imbalance of blood glucose levels in patients, it has been approved by the National Medical Products Administration (NMPA) of China in September 2022. It can be used alone or in combination with metformin hydrochloride-tolerated T2D patients. For those patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required. About 111, Inc. 111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring. For more information on 111, please visit: . Forward-Looking Statements This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. SOURCE 111, Inc.

27 Sep 2021

·www.biospace.com

Hua Medicine May be Sending Type 2 Diabetes into Remission

Is it a DREAM? On September 26, news emerged from Suzhou, China, that a glucokinase activator being developed by Chinese pharmaceutical company Hua Medicine may be heading toward making diabetes remission a reality. “DREAM” is a follow-up, observational clinical study of the Phase III SEED clinical study of dorzagliatin, a first-in-class glucokinase activator, which is being conducted in drug-naive Type 2 diabetes patients to determine its safety and efficacy. Its main objective is to determine if patients who participated in the SEED trial and achieved glycemic control as defined by investigators could maintain this for a minimum of 52 weeks without the intervention of any glucose-lowering medication. And many of them did. The analysis showed a 52-week glucose remission rate of 65.2% among the 69 patients being followed. Professor Jianhua Ma, director of the department of endocrinology at Nanjing First Hospital, standing member of the Chinese Diabetes Society and one of the principal investigators on the study, presented the findings at the 6th China BioMed Innovation and Investment Conference. “Dorzagliatin, a new class of glucokinase activator, has demonstrated the ability to effectively improve early phase insulin secretion and beta cell function and insulin resistance resulting in Type 2 diabetes remission,” Ma said, adding that dorzagliatin monotherapy had previously demonstrated stable long-term efficacy and a good safety pro the SEED study. “The DREAM study again showed positive results, where patients who reached normal blood glucose level after dorzagliatin treatment were able to maintain their blood glucose level and beta cell function after discontinuation of medication.” Ma went on to say that the study is of “great significance in expanding the treatment options for type 2 diabetes.” Hua Medicine is a clinical-stage drug development company based out of Shanghai, China, focussing on novel therapies for the treatment of diabetes and CNS disorders. According to Hua Medicine CEO, founder, and chief scientific officer Dr. Li Chen, China has the world’s largest number of diabetes patients, with the number of type 2 patients exceeding 120 million. He added that prevention and control of diabetes have become a “strategic imperative” in addressing this major public health issue. “The positive results of the DREAM study have strengthened our confidence in the cure of Type 2 diabetes,” Chen said. “Hua Medicine will continue to explore the broad prospects of monotherapy and combination therapy based on dorzagliatin, while further conducting typing studies and using a combination of big data and artificial intelligence for the precise treatment of Type 2 diabetes.” Per the Centers for Disease Control and Prevention (CDC), more than 34 million Americans have diabetes (around 1 in 10), with approximately 90-95% of the cases being Type 2. This is not the first time the idea of diabetes remission has been proposed. In 2020, Dr. Ebaa Al Ozairi, chief medical officer at the Dasman Diabetes Institute in Kuwait said that Type 2 diabetes remission with weight loss is possible and most likely for younger patients who sustain more weight loss and have had the disease for a shorter period of time. “We can no longer talk and tell our patients that diabetes is a chronic disease,” Ozairi, who is also an American Board of Physician Nutrition specialist, said during a presentation at ObesityWeek Interactive. “We have to give them the hope that we know today that diabetes remission is not a myth and is actually a reality. We really need to rethink treatment of Type 2 diabetes, so if it is treated early, we can achieve remission.” In 2018, Danish diabetes leader Novo Nordisk announced that it was upping its focus on stem cell therapy which replaces the beta cells missing in Type 1 diabetes patients with the aim of freeing patients from their dependence on insulin. In February, the company gave an update on its cell therapy efforts, saying that it expected to investigational new drug (IND) application toward the end of 2022, but that the initial indication would be in Parkinson’s disease, not diabetes. In January, Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved an IND for its own cell therapy for Type 1 diabetes. Featured Jobs on BioSpace

First in ClassCell Therapy

26 Apr 2021

·www.biospace.com

Himalaya Therapeutics Announces Appointment of Brian Zhang as Chief Executive Officer

SAN DIEGO, April 26, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization in Greater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics ("CAB") technology platform, today announced the appointment of Brian Zhang, Ph.D., as chief executive officer. "We are thrilled to welcome Dr. Zhang to our growing team. His extensive experience will help drive Himalaya towards its ambitious goals," said Carolyn Short, co-founder and president of Himalaya Therapeutics since its founding in 2014. "Dr. Zhang is our second executive hire this quarter as we ramp up, and will provide great leadership as we continue to build this world-class team." Dr. Zhang is a global pharmaceutical veteran, with decades of experience on the R&D side, overseeing products from discovery to commercialization, on the corporate side, leading and founding healthcare companies, and on the investing side, as a venture partner and an angel investor. While at Hoffmann-La Roche, he helped lead the development of Xenical and the discovery of Dorzagliatin, among others, and helped establish its bioinformatics group. More recently, he cofounded several biotechnology startups and invested in biopharmaceuticals. He received his Ph.D. from the UCLA School of Medicine and his B.S. from Nanjing University. He also conducted brain research at the Chinese Academy of Sciences, earning a grant for further study abroad. "I am excited to join the Himalaya team and look forward to taking the impressive pipeline of a dozen drug candidates to move into the Chinese market as well as globally. The CAB platform has the potential to be truly groundbreaking and applicable to some of the most challenging problems we have faced in our battle against cancer." About Himalaya Therapeutics Himalaya is a global clinical-stage biotechnology company with operations in San Diego, California, and Hong Kong, China. Himalaya is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates, which are designed to have more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing than traditional antibodies, through clinical trials. Its product candidates have been developed using CAB technology, which is protected by more than 500 issued and pending patents. Himalaya has two CAB programs currently in Phase 2 clinical testing in Hong Kong and Taiwan: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing and commercialization in Greater China. Investor Contact: Nicholas Desjardins Himalaya Therapeutics ndesjardins@himalayatherapeutics.com

AntibodyADC

100 Deals associated with Dorzagliatin

External Link

KEGG	Wiki	ATC	Drug Bank
D11342	-	-	DB15123

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	CN	Hua Medicine (Shanghai) Co., Ltd.	30 Sep 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glucose Intolerance	Phase 2	-	The Chinese University of Hong Kong	01 Aug 2022
Maturity-Onset Diabetes of the Young, Type 4	Phase 2	HK	The Chinese University of Hong Kong	30 Sep 2020
Renal Insufficiency	Phase 1	CN	Hua Medicine (Shanghai) Co., Ltd.	25 Apr 2019
Diabetic Nephropathies	IND Application	CN	Hua Medicine (Shanghai) Co., Ltd.	-
Alzheimer Disease	Preclinical	CN	Hua Medicine (Shanghai) Co., Ltd.	13 Oct 2022
Diabetes Mellitus, Type 1	Preclinical	CN	Hua Medicine (Shanghai) Co., Ltd.	13 Oct 2022
Nonalcoholic Steatohepatitis	Preclinical	CN	Hua Medicine (Shanghai) Co., Ltd.	13 Oct 2022
Metabolic Syndrome	Preclinical	CN	Hua Medicine (Shanghai) Co., Ltd.	11 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


DREAM (ADA2022)	Not Applicable	Diabetes Mellitus, Type 2	69	Dorzagliatin	omfvwhahgi(dclbfbgmam) = gmtalbxwxb mlerfhuhqr (uqfdxspnym, 53.4 - 77.0)	-	01 Jun 2022
ADA2022	Not Applicable	Mason-Type Diabetes	8	Dorzagliatin 75mg	tuknbbkwuu(kvuctcsiyk) = nviaqifgmn qttyxmgjaf (nmopxxgyvc ) View more	-	01 Jun 2022
				Placebo	tuknbbkwuu(kvuctcsiyk) = bviizhxcgt qttyxmgjaf (nmopxxgyvc ) View more
NCT03173391 (SEED, Pubmed) Manual	Phase 3	Diabetes Mellitus, Type 2	463	Dorzagliatin	qufmipjkwi(bogcgtrgef) = lssezvyybb aydmbtzymg (gpaerhpunr, -1.19 ~ -0.95)	Positive	12 May 2022
				Placebo	qufmipjkwi(bogcgtrgef) = rjnyeucoiq aydmbtzymg (gpaerhpunr, -0.68 ~ -0.32)
NCT03141073 (DAWN, Pubmed \| Nat Med) Manual	Phase 3	Diabetes Mellitus, Type 2	767	metformin+Dorzagliatin	lpoxmjnfra(ksnwjilpyw) = byanasdbaj cxfraalhkw (qpkzxvppmf, -1.11 to -0.93)	Positive	12 May 2022
				metformin+Placebo	lpoxmjnfra(ksnwjilpyw) = mpaucyhmht cxfraalhkw (qpkzxvppmf, -0.45 to -0.26)
SEED (ADA2021)	Not Applicable	Diabetes Mellitus, Type 2	463	Dorzagliatin 75 mg	duojdnnifq(hnlbimormw) = qxtlmrcpau tgvfqbcequ (osziwxsoas ) View more	Positive	01 Jun 2021
				Placebo	dngnyinjfh(ysssdrehfl) = gjueqqcncd nkzgxmpmlh (edtoufqrpi )
DAWN (ADA2021)	Not Applicable	Diabetes Mellitus, Type 2 Add-on	767	Dorzagliatin	yjriwsiwbh(noajzgbofe) = dyerljmsxz zfmjctryjz (ywyocopfmt )	Positive	01 Jun 2021
				Placebo	yjriwsiwbh(noajzgbofe) = egjlhtszds zfmjctryjz (ywyocopfmt )
NCT03173391 (HMM0301 \| SEED, NEWS) Manual	Phase 3	Diabetes Mellitus, Type 2	463	Dorzagliatin	hsfnuhmkmz(hqgiprzdij) = ipmkgonjpi hjepngwpgf (bkenvyxlvq ) View more	Positive	18 Jun 2020
				Placebo	hsfnuhmkmz(hqgiprzdij) = atfgomdgux hjepngwpgf (bkenvyxlvq ) View more
ADA2020	Not Applicable	Diabetes Mellitus, Type 2	463	Dorzagliatin 75 mg	mdwjhaqepi(houudhiicl) = botnlhqszb qdqlbvbmga (rhmreelmte ) View more	Positive	01 Jun 2020
				Placebo	spqgfagxwm(kgzxmvgdhg) = pixsgyhwhj kxbgpenmrr (izliaembul ) View more
NCT02561338 (CTgov)	Phase 2	Diabetes Mellitus, Noninsulin-Dependent, 2	258	HMS5552 (HMS5552 Dose 1)	kgqbtiudsq(bhxihxeths) = xupjpekbbh hihctrcuuq (jtwvmauwcz, qmsurbzone - aajfmzkget) View more	-	10 Mar 2020
				HMS5552 (HMS5552 Dose 2)	kgqbtiudsq(bhxihxeths) = vagcgzbfkt hihctrcuuq (jtwvmauwcz, gvuhtrdshw - ugiacbuswt) View more
NCT02386982 (Pubmed) Manual	Phase 1	Diabetes Mellitus, Type 2	24	HMS5552 (75 mg twice daily)	rixseajzkm(ufubambvzr) = anrncgfqby bgcykvjadk (ufiaqzxpyl ) View more	Positive	01 Sep 2018
				HMS5552 (75 mg once daily)	rixseajzkm(ufubambvzr) = rpguyerhep bgcykvjadk (ufiaqzxpyl ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis